MEMPHASYS LIMITED. - Announcements

11.1%

0.4¢

Market Cap $7.934M

Technology Scientific & Technical Instruments

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive... Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.More

Corporate Spotlight

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.
View the full Corporate Spotlight

LATEST INTERVIEW

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	11:02	310.37KB	Share
MEM	CE Mark Lodged for Felix to Expand Global Access	PRICE SENSITIVE	30/06/25	311.05KB	Share
MEM	MEM Successfully trials RoXsta Mega Cell High-Throughput	PRICE SENSITIVE	08/05/25	273.42KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	1.61MB	Share
MEM	$1.275M Placement to Accelerate Commercial Rollout	PRICE SENSITIVE	14/04/25	266.46KB	Share
MEM	Trading Halt	PRICE SENSITIVE	10/04/25	196.44KB	Share
MEM	Pause in Trading	PRICE SENSITIVE	10/04/25	115.36KB	Share
MEM	RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle	PRICE SENSITIVE	03/04/25	330.92KB	Share
MEM	Felix Trial Confirms Best-in-Class Performance	PRICE SENSITIVE	24/03/25	245.58KB	Share
MEM	Trading Halt	PRICE SENSITIVE	20/03/25	266.8KB	Share
MEM	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	1.77MB	Share
MEM	Extension of Convertible Notes	PRICE SENSITIVE	28/02/25	173.72KB	Share
MEM	Felix Data lock complete and regulatory submission commenced	PRICE SENSITIVE	24/02/25	235.7KB	Share
MEM	Leading Brazilian Andrology Clinic to test Felix System	PRICE SENSITIVE	17/02/25	225.1KB	Share
MEM	Felix Clinical Trial complete, Data Lock expected in 2 weeks	PRICE SENSITIVE	11/02/25	215.48KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/01/25	510.97KB	Share
MEM	Publication Highlights Diagnostic Potential of RoXsta TM	PRICE SENSITIVE	16/01/25	232.43KB	Share
MEM	Heranova Felix System Utilisation Testing commences in China	PRICE SENSITIVE	06/01/25	229.72KB	Share
MEM	Bovine Study commences to assess RoXsta antioxidant system	PRICE SENSITIVE	20/12/24	243.13KB	Share
MEM	Felix Clinical Registration Study completed, expanding mkt	PRICE SENSITIVE	18/12/24	217.16KB	Share
MEM	Letter of Intent with Heranova for Felix System Distribution	PRICE SENSITIVE	12/12/24	253.74KB	Share
MEM	Order for Felix System to Evaluate Suitability in UAE	PRICE SENSITIVE	05/12/24	228.33KB	Share
MEM	RoXsta System's Potential in Cattle Breeding being Explored	PRICE SENSITIVE	05/12/24	227.51KB	Share
MEM	Felix Clinical Trial Reaches 95% Completion	PRICE SENSITIVE	18/11/24	185.14KB	Share
MEM	RoXsta System Secures Provisional Patent Approval	PRICE SENSITIVE	15/11/24	206.85KB	Share
MEM	Completion of Placement and SPP offer	PRICE SENSITIVE	05/11/24	189.56KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	327.92KB	Share
MEM	MEM Investor Presentation	PRICE SENSITIVE	25/10/24	4.57MB	Share
MEM	Felix Trial registration update	PRICE SENSITIVE	24/10/24	168.27KB	Share
MEM	Equine study commences with 12mth commercialisation expected	PRICE SENSITIVE	18/10/24	179.14KB	Share
MEM	Prospectus	PRICE SENSITIVE	20/09/24	380.04KB	Share
MEM	Short term loan facility	PRICE SENSITIVE	17/09/24	195.35KB	Share
MEM	Positive initial study results - Felix equine application	PRICE SENSITIVE	16/09/24	184.21KB	Share
MEM	Reinstatement to Official Quotation	PRICE SENSITIVE	12/09/24	406.86KB	Share
MEM	A$2 million capital raising	PRICE SENSITIVE	12/09/24	285.01KB	Share
MEM	Voluntary Suspension	PRICE SENSITIVE	11/09/24	229.26KB	Share
MEM	Trading Halt	PRICE SENSITIVE	09/09/24	231.97KB	Share
MEM	Response to ASX Query	PRICE SENSITIVE	06/09/24	776.38KB	Share
MEM	Equine fertility study positions Felix as leading technology	PRICE SENSITIVE	04/09/24	238.42KB	Share
MEM	Preliminary Final Report	PRICE SENSITIVE	30/08/24	1.11MB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	495.49KB	Share
MEM	Felix sales clinical trial and Oxidative Stress devel update	PRICE SENSITIVE	24/07/24	338.25KB	Share
MEM	Animal activity update - oxidative stress measurement system	PRICE SENSITIVE	19/07/24	227.87KB	Share
MEM	Dr David Ali appointed full-time Chief Executive Officer	PRICE SENSITIVE	06/06/24	177.33KB	Share
MEM	Investor Presentation	PRICE SENSITIVE	21/05/24	4.32MB	Share
MEM	Felix Japanese trial provides sperm preparation benefits	PRICE SENSITIVE	20/05/24	212.27KB	Share
MEM	2024 Investor Presentation	PRICE SENSITIVE	09/05/24	4.24MB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/24	389.58KB	Share
MEM	Felix TM System Sales Orders Accelerate in Japan	PRICE SENSITIVE	18/03/24	208.02KB	Share
MEM	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/24	1.53MB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/24	362.42KB	Share
MEM	AI-Port Update - Spring Field Trial Yields Positive Results	PRICE SENSITIVE	25/01/24	230.84KB	Share
MEM	Vitrolife distribution agreement expands into Canada and NZ	PRICE SENSITIVE	02/01/24	198.42KB	Share
MEM	$4.2m raise to pursue commercial opportunities with Felix	PRICE SENSITIVE	04/12/23	241.92KB	Share
MEM	Board and executive transition and capital raise	PRICE SENSITIVE	30/11/23	209.56KB	Share
MEM	Trading Halt	PRICE SENSITIVE	30/11/23	160.49KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	419.5KB	Share
MEM	Felix System records 10 new live births in India	PRICE SENSITIVE	15/09/23	204.58KB	Share
MEM	Preliminary Final Report	PRICE SENSITIVE	30/08/23	1.46MB	Share
MEM	Vitrolife sign Felix distribution agreement for Japanese mkt	PRICE SENSITIVE	07/08/23	180.11KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	381.25KB	Share
MEM	Felix considered best method to treat cryopreserved semen	PRICE SENSITIVE	06/06/23	217.05KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	345.81KB	Share
MEM	Japan first commercial sale and first baby born using Felix	PRICE SENSITIVE	03/04/23	165.54KB	Share
MEM	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/23	1.69MB	Share
MEM	KOL testings demonstrate Felix System outperforms DGC	PRICE SENSITIVE	07/02/23	541.76KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	1.68MB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/22	299.92KB	Share
MEM	FELIX System commercialisation, regulatory plan and trial	PRICE SENSITIVE	24/10/22	173.02KB	Share
MEM	Rights Issue Closure and Shortfall Notification	PRICE SENSITIVE	19/09/22	634.43KB	Share
MEM	Preliminary Final Report	PRICE SENSITIVE	31/08/22	1023.84KB	Share
MEM	Reinstatement to Official Quotation	PRICE SENSITIVE	17/08/22	85.54KB	Share
MEM	$3.36 capital raising to accelerate FELIX commercialisation	PRICE SENSITIVE	17/08/22	236.6KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	1.72MB	Share
MEM	Suspension from Official Quotation	PRICE SENSITIVE	29/07/22	560.19KB	Share
MEM	Trading Halt	PRICE SENSITIVE	27/07/22	150.59KB	Share
MEM	Monash IVF clinical study enrols first patient using FELIX	PRICE SENSITIVE	28/06/22	256.47KB	Share
MEM	Felix System commercialisation update	PRICE SENSITIVE	09/06/22	205.41KB	Share
MEM	Response to ASX Query	PRICE SENSITIVE	17/05/22	219.33KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	12/04/22	309.52KB	Share
MEM	Follow up sales of FelixTM System	PRICE SENSITIVE	30/03/22	198.06KB	Share
MEM	MEM Achieves ISO 13485 Compliance	PRICE SENSITIVE	14/03/22	168.73KB	Share
MEM	Appendix 4D and Half Year Report and Accounts	PRICE SENSITIVE	25/02/22	1.08MB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/22	308.05KB	Share
MEM	First Felix System commercial sale for clinical IVF use	PRICE SENSITIVE	20/12/21	187.71KB	Share
MEM	First Sale of FelixTM in Research Application	PRICE SENSITIVE	22/11/21	229.74KB	Share
MEM	Verification and Validation Assessments Complete	PRICE SENSITIVE	03/11/21	222.28KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	21/10/21	343.4KB	Share
MEM	MEM reaches settlement agreement with Hydrix	PRICE SENSITIVE	01/09/21	234.86KB	Share
MEM	HYD: Commercial arrangement between Hydrix and Memphasys	PRICE SENSITIVE	31/08/21	458.74KB	Share
MEM	Preliminary Final Report	PRICE SENSITIVE	30/08/21	904KB	Share
MEM	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/21	300.08KB	Share
MEM	Memphasys completes $3m capital raise	PRICE SENSITIVE	26/05/21	299.47KB	Share
MEM	Trading Halt	PRICE SENSITIVE	25/05/21	150.18KB	Share
MEM	Quarterly Cashflow Report	PRICE SENSITIVE	30/04/21	162.87KB	Share
MEM	Quarterly Activities Report	PRICE SENSITIVE	30/04/21	201.54KB	Share
MEM	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/21	1.46MB	Share
MEM	Initial Felix product sales update	PRICE SENSITIVE	24/12/20	206.7KB	Share
MEM	FELIX verification and validation update	PRICE SENSITIVE	19/11/20	295.59KB	Share
MEM	Preliminary Final Report	PRICE SENSITIVE	27/08/20	1.03MB	Share

MEM Quarterly Activities/Appendix 4C Cash Flow Report
11:02	PRICE SENSITIVE	310.37KB	Share
MEM CE Mark Lodged for Felix to Expand Global Access
30/06/25	PRICE SENSITIVE	311.05KB	Share
MEM MEM Successfully trials RoXsta Mega Cell High-Throughput
08/05/25	PRICE SENSITIVE	273.42KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	1.61MB	Share
MEM $1.275M Placement to Accelerate Commercial Rollout
14/04/25	PRICE SENSITIVE	266.46KB	Share
MEM Trading Halt
10/04/25	PRICE SENSITIVE	196.44KB	Share
MEM Pause in Trading
10/04/25	PRICE SENSITIVE	115.36KB	Share
MEM RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle
03/04/25	PRICE SENSITIVE	330.92KB	Share
MEM Felix Trial Confirms Best-in-Class Performance
24/03/25	PRICE SENSITIVE	245.58KB	Share
MEM Trading Halt
20/03/25	PRICE SENSITIVE	266.8KB	Share
MEM Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	1.77MB	Share
MEM Extension of Convertible Notes
28/02/25	PRICE SENSITIVE	173.72KB	Share
MEM Felix Data lock complete and regulatory submission commenced
24/02/25	PRICE SENSITIVE	235.7KB	Share
MEM Leading Brazilian Andrology Clinic to test Felix System
17/02/25	PRICE SENSITIVE	225.1KB	Share
MEM Felix Clinical Trial complete, Data Lock expected in 2 weeks
11/02/25	PRICE SENSITIVE	215.48KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
23/01/25	PRICE SENSITIVE	510.97KB	Share
MEM Publication Highlights Diagnostic Potential of RoXsta TM
16/01/25	PRICE SENSITIVE	232.43KB	Share
MEM Heranova Felix System Utilisation Testing commences in China
06/01/25	PRICE SENSITIVE	229.72KB	Share
MEM Bovine Study commences to assess RoXsta antioxidant system
20/12/24	PRICE SENSITIVE	243.13KB	Share
MEM Felix Clinical Registration Study completed, expanding mkt
18/12/24	PRICE SENSITIVE	217.16KB	Share
MEM Letter of Intent with Heranova for Felix System Distribution
12/12/24	PRICE SENSITIVE	253.74KB	Share
MEM Order for Felix System to Evaluate Suitability in UAE
05/12/24	PRICE SENSITIVE	228.33KB	Share
MEM RoXsta System's Potential in Cattle Breeding being Explored
05/12/24	PRICE SENSITIVE	227.51KB	Share
MEM Felix Clinical Trial Reaches 95% Completion
18/11/24	PRICE SENSITIVE	185.14KB	Share
MEM RoXsta System Secures Provisional Patent Approval
15/11/24	PRICE SENSITIVE	206.85KB	Share
MEM Completion of Placement and SPP offer
05/11/24	PRICE SENSITIVE	189.56KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	327.92KB	Share
MEM MEM Investor Presentation
25/10/24	PRICE SENSITIVE	4.57MB	Share
MEM Felix Trial registration update
24/10/24	PRICE SENSITIVE	168.27KB	Share
MEM Equine study commences with 12mth commercialisation expected
18/10/24	PRICE SENSITIVE	179.14KB	Share
MEM Prospectus
20/09/24	PRICE SENSITIVE	380.04KB	Share
MEM Short term loan facility
17/09/24	PRICE SENSITIVE	195.35KB	Share
MEM Positive initial study results - Felix equine application
16/09/24	PRICE SENSITIVE	184.21KB	Share
MEM Reinstatement to Official Quotation
12/09/24	PRICE SENSITIVE	406.86KB	Share
MEM A$2 million capital raising
12/09/24	PRICE SENSITIVE	285.01KB	Share
MEM Voluntary Suspension
11/09/24	PRICE SENSITIVE	229.26KB	Share
MEM Trading Halt
09/09/24	PRICE SENSITIVE	231.97KB	Share
MEM Response to ASX Query
06/09/24	PRICE SENSITIVE	776.38KB	Share
MEM Equine fertility study positions Felix as leading technology
04/09/24	PRICE SENSITIVE	238.42KB	Share
MEM Preliminary Final Report
30/08/24	PRICE SENSITIVE	1.11MB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	495.49KB	Share
MEM Felix sales clinical trial and Oxidative Stress devel update
24/07/24	PRICE SENSITIVE	338.25KB	Share
MEM Animal activity update - oxidative stress measurement system
19/07/24	PRICE SENSITIVE	227.87KB	Share
MEM Dr David Ali appointed full-time Chief Executive Officer
06/06/24	PRICE SENSITIVE	177.33KB	Share
MEM Investor Presentation
21/05/24	PRICE SENSITIVE	4.32MB	Share
MEM Felix Japanese trial provides sperm preparation benefits
20/05/24	PRICE SENSITIVE	212.27KB	Share
MEM 2024 Investor Presentation
09/05/24	PRICE SENSITIVE	4.24MB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
29/04/24	PRICE SENSITIVE	389.58KB	Share
MEM Felix TM System Sales Orders Accelerate in Japan
18/03/24	PRICE SENSITIVE	208.02KB	Share
MEM Half Yearly Report and Accounts
26/02/24	PRICE SENSITIVE	1.53MB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
25/01/24	PRICE SENSITIVE	362.42KB	Share
MEM AI-Port Update - Spring Field Trial Yields Positive Results
25/01/24	PRICE SENSITIVE	230.84KB	Share
MEM Vitrolife distribution agreement expands into Canada and NZ
02/01/24	PRICE SENSITIVE	198.42KB	Share
MEM $4.2m raise to pursue commercial opportunities with Felix
04/12/23	PRICE SENSITIVE	241.92KB	Share
MEM Board and executive transition and capital raise
30/11/23	PRICE SENSITIVE	209.56KB	Share
MEM Trading Halt
30/11/23	PRICE SENSITIVE	160.49KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	419.5KB	Share
MEM Felix System records 10 new live births in India
15/09/23	PRICE SENSITIVE	204.58KB	Share
MEM Preliminary Final Report
30/08/23	PRICE SENSITIVE	1.46MB	Share
MEM Vitrolife sign Felix distribution agreement for Japanese mkt
07/08/23	PRICE SENSITIVE	180.11KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	381.25KB	Share
MEM Felix considered best method to treat cryopreserved semen
06/06/23	PRICE SENSITIVE	217.05KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	345.81KB	Share
MEM Japan first commercial sale and first baby born using Felix
03/04/23	PRICE SENSITIVE	165.54KB	Share
MEM Half Yearly Report and Accounts
24/02/23	PRICE SENSITIVE	1.69MB	Share
MEM KOL testings demonstrate Felix System outperforms DGC
07/02/23	PRICE SENSITIVE	541.76KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	1.68MB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
27/10/22	PRICE SENSITIVE	299.92KB	Share
MEM FELIX System commercialisation, regulatory plan and trial
24/10/22	PRICE SENSITIVE	173.02KB	Share
MEM Rights Issue Closure and Shortfall Notification
19/09/22	PRICE SENSITIVE	634.43KB	Share
MEM Preliminary Final Report
31/08/22	PRICE SENSITIVE	1023.84KB	Share
MEM Reinstatement to Official Quotation
17/08/22	PRICE SENSITIVE	85.54KB	Share
MEM $3.36 capital raising to accelerate FELIX commercialisation
17/08/22	PRICE SENSITIVE	236.6KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	1.72MB	Share
MEM Suspension from Official Quotation
29/07/22	PRICE SENSITIVE	560.19KB	Share
MEM Trading Halt
27/07/22	PRICE SENSITIVE	150.59KB	Share
MEM Monash IVF clinical study enrols first patient using FELIX
28/06/22	PRICE SENSITIVE	256.47KB	Share
MEM Felix System commercialisation update
09/06/22	PRICE SENSITIVE	205.41KB	Share
MEM Response to ASX Query
17/05/22	PRICE SENSITIVE	219.33KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
12/04/22	PRICE SENSITIVE	309.52KB	Share
MEM Follow up sales of FelixTM System
30/03/22	PRICE SENSITIVE	198.06KB	Share
MEM MEM Achieves ISO 13485 Compliance
14/03/22	PRICE SENSITIVE	168.73KB	Share
MEM Appendix 4D and Half Year Report and Accounts
25/02/22	PRICE SENSITIVE	1.08MB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
25/01/22	PRICE SENSITIVE	308.05KB	Share
MEM First Felix System commercial sale for clinical IVF use
20/12/21	PRICE SENSITIVE	187.71KB	Share
MEM First Sale of FelixTM in Research Application
22/11/21	PRICE SENSITIVE	229.74KB	Share
MEM Verification and Validation Assessments Complete
03/11/21	PRICE SENSITIVE	222.28KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
21/10/21	PRICE SENSITIVE	343.4KB	Share
MEM MEM reaches settlement agreement with Hydrix
01/09/21	PRICE SENSITIVE	234.86KB	Share
MEM HYD: Commercial arrangement between Hydrix and Memphasys
31/08/21	PRICE SENSITIVE	458.74KB	Share
MEM Preliminary Final Report
30/08/21	PRICE SENSITIVE	904KB	Share
MEM Quarterly Activities/Appendix 4C Cash Flow Report
26/07/21	PRICE SENSITIVE	300.08KB	Share
MEM Memphasys completes $3m capital raise
26/05/21	PRICE SENSITIVE	299.47KB	Share
MEM Trading Halt
25/05/21	PRICE SENSITIVE	150.18KB	Share
MEM Quarterly Cashflow Report
30/04/21	PRICE SENSITIVE	162.87KB	Share
MEM Quarterly Activities Report
30/04/21	PRICE SENSITIVE	201.54KB	Share
MEM Half Yearly Report and Accounts
26/02/21	PRICE SENSITIVE	1.46MB	Share
MEM Initial Felix product sales update
24/12/20	PRICE SENSITIVE	206.7KB	Share
MEM FELIX verification and validation update
19/11/20	PRICE SENSITIVE	295.59KB	Share
MEM Preliminary Final Report
27/08/20	PRICE SENSITIVE	1.03MB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change -0.001(11.1%)		Mkt cap ! $7.934M

Open	High	Low	Value	Volume
0.5¢	0.5¢	0.4¢	$60.70K	15.16M

Buyers (Bids)

No.	Vol.	Price($)
9	4460257	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	1066202	2

View Market Depth

No.	Vol.	Price($)
9	4460257	0.003
8	5494011	0.002
6	9750024	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	1066202	2
0.005	5087626	10
0.006	5039975	12
0.007	8989817	6
0.008	1782500	5

Last trade - 15.12pm 30/07/2025 (20 minute delay)


Last 0.4¢		Change -0.001 ( 11.1 %)
Open	High	Low	Volume
0.5¢	0.5¢	0.4¢	4996013
Last updated 15.36pm 30/07/2025 ?

MEM (ASX) Chart

MEMPHASYS LIMITED. - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories